Spots Global Cancer Trial Database for Haplo HCT vs Haplo-cord HCT for Patients With AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Haplo HCT vs Haplo-cord HCT for Patients With AML
Official Title: An Open-label, Multicenter, Randomized, Phase 3 Trial to Assess the Efficacy and Safety of Coinfusion With Unrelated Cord Blood Unit for Patients With Acute Myeloid Leukemia Undergoing Haploidentical Hematopoietic Cell Transplantation
Study ID: NCT03719534
Study Description
Brief Summary: Patients who have acute myeloid leukemia and will undergo haplo-identical donor hematopoeitic cell transplantation (haplo HCT) are potential candidates of this trial. Participants will randomized into two arms: Arm A will undergo a typical haplo HCT, while Arm B will receive an coinfusion of an unrelated cord blood unit (haplo-cord HCT) in addition to Arm A. Progression-free survival, overall survival, cumulative incidence of relapse and nonrelapse mortality will be recorded as endpoints.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Soochow Hopes Hematology Hospital, Suzhou, Jiangsu, China
Hygeia Suzhou Yongding Hospital, Suzhou, Jiangsu, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact Details
Name: Depei Wu, M.D., Ph.D.
Affiliation: The First Affiliated Hospital of Soochow University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
